[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies

Dan Cohen(Tel Aviv Sourasky Medical Center), Einat Even‐Sapir(Tel Aviv University), Yael Bar‐On(Tel Aviv University), Ron Ram(Tel Aviv University), Odelia Amit(Tel Aviv University), Chava Perry(Tel Aviv University), Shir Hazut Krauthammer(Tel Aviv Sourasky Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Efrat Luttwak(Tel Aviv University), Ronit Gold(Tel Aviv University), Ofrat Beyar‐Katz(Rambam Health Care Campus)
European Journal of Nuclear Medicine and Molecular Imaging
September 4, 2021
10.1007/s00259-021-05551-5
Cited by 58

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
|Cancer|2012|108
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
|Cancer Research|2018|103